Dasatinib and Itraconazole (Itraxyl 100 mg): interaction and safety
This source-based reference is not a personal treatment recommendation. The relevance and management of an interaction depend on the exact products, route, dose and clinical situation.
Interaction mechanism
Strong CYP3A inhibition can reduce dasatinib metabolism and increase systemic exposure.
Clinical significance and safety
Itraxyl 100 mg contains itraconazole, a systemic strong CYP3A inhibitor. It may raise dasatinib exposure and increase treatment-related toxicity. The cited label advises avoiding strong CYP3A inhibition; an unavoidable combination needs an oncology-directed plan. Do not alter either prescription independently.
Using this information
This is a source-based reference record, not a recommendation to combine, stop or change medicines. A missing interaction record does not establish safe use. A qualified healthcare professional should consider the exact products, doses, other medicines and individual health circumstances.